Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332770 | 0.91 | CASP3 (0.36) | CASP3KMT2AFBP1 | |
| SCHEMBL13302768 | 0.82 | MEN1 (0.34) | CASP3CMA1KMT2A | |
| SCHEMBL3336261 | 0.79 | CASP3 (0.37) | CASP3CMA1KMT2AFBP1ALDH1A1 | |
| SCHEMBL3338358 | 0.77 | CMA1 (0.40) | CMA1KMT2APARP1ALDH1A1 | |
| SCHEMBL3335635 | 0.71 | TPSAB1 (0.41) | CASP3CMA1FBP1 | |
| SCHEMBL27045518 | 0.70 | KMT2A (0.52) | CMA1KMT2AGAAALDH1A1 | |
| SCHEMBL16989311 | 0.70 | KMT2A (0.52) | CMA1KMT2AGAAALDH1A1 | |
| SCHEMBL20479216 | 0.70 | KMT2A (0.52) | CMA1KMT2AGAAALDH1A1 | |
| SCHEMBL16989098 | 0.70 | ALDH1A1 (0.47) | CMA1KMT2AGAAALDH1A1 | |
| SCHEMBL3330810 | 0.70 | ATM (0.41) | CMA1KMT2AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | CASP3 1852/4885CMA1 12/4885KMT2A 1432/4885 |
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | CASP3 1852/4885CMA1 12/4885KMT2A 1432/4885 |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | CASP3 1852/4885CMA1 12/4885KMT2A 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.